Trials / Completed
CompletedNCT01393951
A Study to Evaluate the Immune Response to the ASP7374 and Its Safety in Healthy Adult Volunteers
Study for Immunogenicity and Safety of ASP7374 for Subcutaneous and Intramuscular Vaccination in Healthy Adults
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 165 (actual)
- Sponsor
- UMN Pharma Inc. · Industry
- Sex
- All
- Age
- 20 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
This trial is designed as a blinded, randomized and parallel group study to investigate the clinically recommended dosage for ASP7374 based on the comparison of the immunogenicity and safety among two doses of subcutaneous ASP7374 and one dose of intramuscular ASP7374 in healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ASP7374 | subcutaneous and intramuscular |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2011-07-14
- Last updated
- 2017-09-29
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01393951. Inclusion in this directory is not an endorsement.